^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Ampulla of Vater Carcinoma

7d
Spatial transcriptomics profiling of small intestine adenocarcinoma and adenoma in humans and a murine model with KRASG12D and loss of CDKN2a-p16. (PubMed, Am J Pathol)
A novel genetically engineered mouse model that mimics gastric-type and intestinal-type adenomas and gastric-type SIAC/EDA is reported. Spatial transcriptomics provided a detailed understanding of cellular differentiation lineages, cancer microenvironment related to SIAC subtypes and driving pathways that may be leveraged to identify new molecular tools for pathologic diagnosis and potential targets for precision cancer therapies.
Preclinical • Journal
|
KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
|
KRAS G12D • KRAS G12
8d
Duodenal ampullary neuroendocrine tumor, high risk gastrointestinal stromal tumor, and gastric leiomyoma in a patient with neurofibromatosis type 1: a rare case report and literature review. (PubMed, Front Oncol)
No adjuvant therapy was administered due to the absence of residual disease and actionable mutations. This case highlights the broad tumor spectrum in NF1 and underscores the importance of comprehensive imaging, multidisciplinary management, and genetic testing for optimal outcomes.
Journal
|
NF1 (Neurofibromin 1)
11d
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers (clinicaltrials.gov)
P=N/A, N=15, Recruiting, University of California, Irvine | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
Trial completion date • Trial primary completion date • Circulating tumor DNA
14d
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes (clinicaltrials.gov)
P=N/A, N=360, Recruiting, Cedars-Sinai Medical Center | Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Apr 2026 --> Jan 2027
Trial completion date • Trial primary completion date
22d
Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas. (PubMed, Int J Mol Sci)
In selected fit patients, modified FOLFIRINOX may address mixed phenotypes...Research priorities include ampulla-enriched umbrella trials, explicit AC subcohorts in tissue-agnostic studies, and ctDNA-informed endpoints. This lineage-first, mutation-fast paradigm supports precision care and evidence generation in AC.
Review • Journal • MSi-H Biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • KRAS mutation • MSI-H/dMMR • HER-2 amplification • BRAF V600 • RET fusion
|
5-fluorouracil • irinotecan • leucovorin calcium
25d
Recurrence patterns and predictors after pancreaticoduodenectomy for ampullary carcinoma. (PubMed, HPB (Oxford))
Recurrence is predominantly systemic and driven by nodal status and CA19‑9, adjuvant chemotherapy mitigates distant failure-particularly in N1-and the identification of delayed gastric emptying as an independent predictor underscores the oncologic importance of perioperative optimization; histologic subtype was not independently prognostic.
Journal
|
CA 19-9 (Cancer antigen 19-9)
1m
Clinical characteristics of ampullary tumors and analysis of the efficacy and safety of endoscopic papillectomy (ChiCTR2500112237)
P=N/A, N=182, Not yet recruiting, Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital; Department of Gastroenterology, The First Medical Center of
New trial
1m
The Impact of Braun Anastomosis with Different Lengths of Output Loop on the Major Clinical Outcomes After Pancreatectomy: A Prospective, Randomized, Controlled, Multicenter Clinical Study (ChiCTR2600116777)
P=N/A, N=60, Recruiting, The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University
New trial
1m
Association Between Tumor-Infiltrating Immune Cells and Early Recurrence in Ampulla of Vater Carcinoma. (PubMed, Cureus)
However, the present results should be interpreted as exploratory and hypothesis-generating. Further large-scale studies are warranted to clarify the biological significance of these immune features and their potential therapeutic implications.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3) • CA 19-9 (Cancer antigen 19-9)
1m
Pancreatic cancer risk and survival in patients with Lynch syndrome: a nationwide Dutch cohort study. (PubMed, EClinicalMedicine)
These findings suggest that current surveillance recommendations for individuals with LS should be re-evaluated. Lynch-Polyposis.
Journal
|
MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2) • EPCAM (Epithelial cell adhesion molecule)
1m
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy (clinicaltrials.gov)
P=N/A, N=90, Recruiting, Minia University | Not yet recruiting --> Recruiting
Enrollment open